AstraZeneca has been stockpiling medications in case Brexit disrupts the flow of products between the UK and EU.
The company reportedly always has a surplus of products on hand — but it has increased its stored medication amount by 20 percent. According to the company, there are concerns that once Brexit goes into effect, manufacturers could be subjected to duplicate testing and product validation on both sides of the English Channel.
An estimated 45 million patient packs are sent from the UK to the EU every month while 37 million are sent the other way. AstraZeneca and other pharma companies have publically expressed their preference to stay in the EU regulatory system after Brexit.
Read the full Reuters report.